Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study

BACKGROUND: Cardiotoxicity is an adverse effect of trastuzumab (TRA) in the treatment of human epidermal growth factor 2 positive (HER2+) breast cancer. Current literature on the cardioprotective effects of agents targeted against the renin-angiotensin-aldosterone system (RAAS) and beta-blockers (BB...

Descripción completa

Detalles Bibliográficos
Autores principales: Moey, Melissa Y. Y., Liles, Darla K., Carabello, Blase A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048102/
https://www.ncbi.nlm.nih.gov/pubmed/32154015
http://dx.doi.org/10.1186/s40959-019-0043-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048102/
https://www.ncbi.nlm.nih.gov/pubmed/32154015
http://dx.doi.org/10.1186/s40959-019-0043-8

Ejemplares similares